GO
Loading...

Merck & Co Inc

More

  • FDA OKs Merck tablet to reduce ragweed allergies Thursday, 17 Apr 2014 | 3:56 PM ET

    WHITEHOUSE STATION, N.J.— U.S. regulators have again approved a Merck& Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen. The Food and Drug Administration approved it for patients aged 18 through 65.. Whitehouse Station, N.J.- based Merck's tablet for spring grass allergies, Grastek, was approved Monday for patients aged 5 to 65..

  • Merck's ragweed pollen allergy drug gets U.S. approval Thursday, 17 Apr 2014 | 3:00 PM ET

    April 17- The U.S. Food and Drug Administration has approved Merck& Co's pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis.

  • Jobs outlook for Class of 2014 looks like this... Wednesday, 16 Apr 2014 | 1:14 PM ET

    Job prospects for this year's college graduates have changed a lot from last year, according to a new survey.

  • Smartphone apps remind patients to take their meds Wednesday, 16 Apr 2014 | 12:48 PM ET

    Medicine only helps if you take it properly. Still, only about half of patients take medication as prescribed, resulting in unnecessary hospital admissions and ER visits that cost the U.S. health care system an estimated $290 billion a year. Michael A. Weber, a cardiologist at SUNY Downstate Medical Center.

  • FDA OKs Merck tablet to reduce grass allergies Tuesday, 15 Apr 2014 | 3:15 PM ET

    WHITEHOUSE STATION, N.J.— Merck& Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old. Merck, based in Whitehouse Station, N.J., will market the tablet in North America. Its partner, ALK-Abello, sells it in Europe as Grazas.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • April 14- Merck& Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.

  • LOS ANGELES/ LONDON April 11- Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

  • April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

  • U.S. stocks rose on Wednesday after Alcoa's quarterly profit topped expectations.

  • Over $2 trillion in untaxed US profits held overseas Wednesday, 9 Apr 2014 | 7:06 AM ET

    Foreign profits held overseas by U.S. corporations to avoid taxes at home nearly doubled from 2008 to 2013 to top $2.1 trillion.

  • LONDON, April 9- The World Health Organisation wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.

  • *GE tops list, followed by Microsoft, Pfizer, Merck, Apple. WASHINGTON, April 8- Foreign profits held overseas by U.S. corporations to avoid taxes at home nearly doubled from 2008 to 2013 to top $2.1 trillion, said a private research firm's report, prompting a call for reform by the Senate's top tax law writer.

  • Fort Hood shootings could stymie veteran hiring Tuesday, 8 Apr 2014 | 8:32 AM ET
    Gen. Mark Milley speaks during a news conference on April 3, 2014, a day after the shootings.

    "PTSD is the big giant elephant in the boardroom that a lot of people worry about but nobody talks about," a psychiatrist says.

  • April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. Alkermes success comes about a week after Australia- based Prana Biotechnology said its experimental drug to treat Alzheimer's disease failed a mid-stage study.

  • *Chicago Board of Trade wheat for May delivery was up 1-3/ 4 cents at $6.71-1/ 2 a bushel by 0044 GMT. Soybeans were nearly flat at $14.74. *China has still not approved a gene-modified strain of corn known as MIR162, prolonging a ban that has seen nearly 1 million tonnes of the U.S. grain turned away from Chinese ports since November.

  • LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.

  • Maybe this isn't a bubble after all: Cramer Tuesday, 1 Apr 2014 | 1:14 PM ET

    The S&P has made an all-time high for nine-straight quarters, but CNBC's Jim Cramer says there's reason to think it's sustainable.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.